We therefore hypothesized that a YY1-STAT3 or STAT3-YY1 signaling axis may influence the initiation of cardiac fibrosis in DCM, and that identifying effective agents that inhibit this signaling axis may be beneficial for treating DCM. This evidence concerns the gene STAT3 and familial dilated cardiomyopathy.